Projects per year
Personal profile
Research Strategic Pillar
Dr. Randall Urban, VP and Chief Research Officer, has determined that UTMB research should be prioritized into six health communities. This researcher has received the following badge(s):
Research interests
Dr. Cross’ research is centered on the biology and pathogenesis of high priority viral agents with a particular emphasis on elucidating mechanisms of vascular leak, coagulopathy, and immune derangement in viral hemorrhagic fever infections caused by filoviruses, arenaviruses, and bunyaviruses. His work utilizes a systems biology, molecular virology, and comparative pathogenesis approaches which utilize in vitro and in vivo models which accurately recapitulate human disease. The goal of this work is to dissect the events leading to disease or survival in order to develop medical countermeasures including vaccines, therapeutics, and diagnostics. Dr. Cross also has a long standing interest in the epidemiology and ecology of these viruses where a particular focus has been centered on mammalian reservoirs of viral infection.
Research Strategic Pillar Keywords
- Brain Health
- Life Span Health
- Infectious/ Immunological Health
- Specialized Health
Fingerprint
- 1 Similar Profiles
Collaborations and top research areas from the last five years
-
Natural History Studies of Henipaviruses and Emerging Bat Borne Viruses
Cross, R. (PI)
US Department of Agriculture-ARS
8/22/22 → 4/30/27
Project: Research project
-
Pathogenic Mammarenavirus and Orthohantavirus in Argentina
Cross, R. (PI)
7/1/23 → 11/30/24
Project: Research project
-
Natural history of nonhuman primates after conjunctival exposure to Ebola virus
Cross, R. W., Prasad, A. N., Woolsey, C. B., Agans, K. N., Borisevich, V., Dobias, N. S., Comer, J. E., Deer, D. J., Geisbert, J. B., Rasmussen, A. L., Lipkin, W. I., Fenton, K. A. & Geisbert, T. W., Dec 2023, In: Scientific reports. 13, 1, 4175.Research output: Contribution to journal › Article › peer-review
Open Access -
A Recombinant Chimeric Cedar Virus-Based Surrogate Neutralization Assay Platform for Pathogenic Henipaviruses
Amaya, M., Yin, R., Yan, L., Borisevich, V., Adhikari, B. N., Bennett, A., Malagon, F., Cer, R. Z., Bishop-Lilly, K. A., Dimitrov, A. S., Cross, R. W., Geisbert, T. W. & Broder, C. C., May 2023, In: Viruses. 15, 5, 1077.Research output: Contribution to journal › Article › peer-review
Open Access -
Erratum: Combination treatment of mannose and GalNAc conjugated small interfering RNA protects against lethal Marburg virus infection (Molecular Therapy (2023) 31(1) (269–281), (S1525001622005639), (10.1016/j.ymthe.2022.09.009))
Ye, X., Holland, R., Wood, M., Pasetka, C., Palmer, L., Samaridou, E., McClintock, K., Borisevich, V., Geisbert, T. W., Cross, R. W. & Heyes, J., Mar 1 2023, In: Molecular Therapy. 31, 3, p. 911-912 2 p.Research output: Contribution to journal › Comment/debate › peer-review
Open Access -
Recombinant vesicular stomatitis virus–vectored vaccine induces long-lasting immunity against Nipah virus disease
Woolsey, C., Borisevich, V., Fears, A. C., Agans, K. N., Deer, D. J., Prasad, A. N., O’Toole, R., Foster, S. L., Dobias, N. S., Geisbert, J. B., Fenton, K. A., Cross, R. W. & Geisbert, T. W., Feb 1 2023, In: Journal of Clinical Investigation. 133, 3, e164946.Research output: Contribution to journal › Article › peer-review
Open Access -
Combination treatment of mannose and GalNAc conjugated small interfering RNA protects against lethal Marburg virus infection
Ye, X., Holland, R., Wood, M., Pasetka, C., Palmer, L., Samaridou, E., McClintock, K., Borisevich, V., Geisbert, T. W., Cross, R. W. & Heyes, J., Jan 4 2023, In: Molecular Therapy. 31, 1, p. 269-281 13 p.Research output: Contribution to journal › Article › peer-review
Open Access